RENEGADE: Radioembolization for Early Stage Renal Cell Carcinoma: An Open-Label, Prospective, Multi-Center, Phase 1/2 Safety Trial
To assess safety and toxicity of yttrium-90 radioembolization for Renal Cell Carcinoma (RCC)
Why this Research Matters
Patients with RCC (Stage T1 or T2a) who are not eligible for treatment with resection or ablation.
Who can Participate
Adult
- 18 years or older - Life expectancy greater than 12 months - Diagnosed with kidney cancer (renal cell carcinoma) - Not an ideal candidate for partial nephrectomy or thermal ablation at the time of study entry - Not considered a candidate for long-term tumor surveillance - Absence of bilateral renal tumors Study participation will last about 24 months.
Study ID
Protocol Number: 24-1681
More information available at ClinicalTrials.gov: NCT06432036
Meet the Team
Principal Investigator